Literature DB >> 2859849

Central effects of H1 and H2 antihistamines.

A N Nicholson.   

Abstract

H1-antihistamines are usually associated with impairment of central nervous functions, but unacceptable decrements in performance may not be an inevitable sequel of their use. Effects are dependent on the ability of a particular drug to cross the blood brain barrier, and so compounds which cross so slowly that tolerance of the central nervous system can develop gradually without any immediate changes in performance are of interest. However, sustained release formulations and compounds which have a selective affinity for the peripheral receptor may also have their part to play in the management of allergic states in those involved in skilled activity. As far as H2-antagonists are concerned, it is likely that as they are less liposoluble they would be free of central effects. Studies on the central effects of H1 and H2 antagonists are reviewed, and tentative recommendations are made in respect of these findings concerning the possible use of these drugs in aircrew.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859849

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  4 in total

1.  Promethazine, scopolamine and cinnarizine: comparative time course of psychological performance effects.

Authors:  A C Parrott; K Wesnes
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine.

Authors:  N Okamura; K Yanai; M Higuchi; J Sakai; R Iwata; T Ido; H Sasaki; T Watanabe; M Itoh
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

Review 3.  Effects of antihistamine medications on exercise performance. Implications for sportspeople.

Authors:  L C Montgomery; P A Deuster
Journal:  Sports Med       Date:  1993-03       Impact factor: 11.136

4.  Studies on the central effects of the H1-antagonist, loratadine.

Authors:  C M Bradley; A N Nicholson
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.